• AUD $5.3 million R&D Tax Incentive Rebate received
• 2nd CRADA signed with U.S. Army to advance RECCE® 327 Gel for burn wounds
• Brazil patent granted for RECCE® Anti-Infectives

Recce Pharmaceuticals Ltd reported its Q3 FY2026 results, highlighting key operational achievements. The company received a AUD $5.3 million R&D Tax Incentive Rebate from the Australian Taxation Office for FY2025, and expects an additional AUD $3.5 million in the coming weeks. Recce also signed a second Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research to evaluate RECCE® 327 Gel for burn wound infections. This builds on the company's existing collaboration with the U.S. government. Additionally, Recce's RECCE® Anti-Infectives patent was granted in Brazil, strengthening the company's intellectual property portfolio. The Brazilian patent covers the process for preparing RECCE® anti-infectives and their use in treating various infections. Recce also hosted a key opinion leader webinar providing updates on its Registrational Phase 3 Clinical Trial for Diabetic Foot Infections in Indonesia and the U.S. Department of War burn wound program. The company ended the quarter with AUD $1.7 million in cash, with net cash inflows from operating activities of AUD $1.6 million.

The company expects to receive an additional AUD $3.5 million R&D tax rebate in the coming weeks, providing further non-dilutive funding to support its clinical and commercial objectives.

Recce continues to advance key value-driving programs in parallel, including the Registrational Phase 3 clinical trial in Indonesia for R327G, the U.S. Department of War burn wound program, and the expansion of its intellectual property portfolio globally. The company is also engaged in multiple licensing negotiations in support of its late-stage clinical assets and market opportunities.